SOLICITATION NOTICE
B -- Attribution of Blame by Physicians: Perceptions of Generic and Branded Products
- Notice Date
- 8/18/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Division of Contracts and Procurement Management, Office of Facilities, Acquisitions, and Central Svcs 5600 Fishers Lane, HFA-511, Rockville, MD, 20857
- ZIP Code
- 20857
- Solicitation Number
- Reference-Number-D39242
- Response Due
- 9/2/2003
- Archive Date
- 9/17/2003
- Point of Contact
- Stephanie Hawk, Buyer, Phone 301-827-7886, Fax 301-594-2127,
- E-Mail Address
-
hawks@cder.fda.gov
- Description
- This is a combined synopsis/solicitation for commercial items or services prepared in accordance with the format in FAR Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a written solicitation will not be issued. This solicitation is issued as a Request for Quote (RFQ) No. D39242. These solicitation clauses and provisions are those in effect through Federal Acquisition Circular 97-27. The Standard Industrial Classification (SIC) Code for this acquisition is B542 and the North American Classification System (NAICS) Code is 541720. The FDA intends to issue a purchase order on a sole source basis to University of Mississippi School of Pharmacy for the following service entitled: The purpose of this project is to explore the blame that physicians place on generic and branded drug products for adverse drug events as compared to other entities (e.g., physician, health plan, FDA); to explore the relationship between knowledge of bioequivalence testing and propensity to substitute and blame placed on generic and branded drug products by physicians; and to explore the relationship between adverse drug event severity and the blame placed on generic and branded drug products by physicians. Period of Performance is six months from date of award. Deliverables: a self administered questionnaire will be used. Three mailings will be sent to a sample of 5,000 physicians from all parts of the U.S. The sample also will include a variety of primary care practitioners and specialists. These specialties were chosen to ensure a broad range of likely adverse drug events and variability in the propensity to substitute. The results will be compiled in a report and presented to the Office along with suggestions on how to address misconceptions. The following FAR Clauses shall apply to this solicitation: 52.213-4 TERMS AND CONDITIONS-SIMPLIFIED ACQUISITIONS (OTHER THAN COMMERCIAL ITEMS) (JUNE 2003); and 52.232-33 Electronic Funds Transfers. All responsible sources that can provide and meet the above requirements shall submit written quotations by the due date referenced above. The award is being issued on a sole source basis because the University of Mississippi has a premier pharmacy department and is the leading research entity for issues related to variable physician reluctance to use generic drugs for all therapies. This is the exact information that is needed for the campaign. FAR provisions can be found on the following website: http://www/arnet.gov. Questions regarding this solicitiation can be addressed by phone (240-453-6709) or e-mail (hawks@cder.fda.gov) to Stephanie Hawk.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/FDA/DCPM/Reference-Number-D39242/listing.html)
- Place of Performance
- Address: FDA/CDER/OPS 1451 Rockville Pike Rockville, Maryland
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN00405688-F 20030820/030818224050 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |